NasdaqGM:EOLSPharmaceuticals
Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum
Evolus stock just ripped almost 20% higher to US$7.41, and the move is all about one thing. The market is latching onto a margin and profitability turn that feels very different from the company investors watched over the past year.
Q2 revenue of US$84.1m, helped by aesthetics demand across toxins and fillers, arrived alongside a third straight quarter of positive adjusted earnings before interest, taxes, depreciation and amortization. That shift in earnings quality is what traders are...